Ozempic maker takes $107 billion hit as alarm bells ring louder

At its peak in June 2024, Novo was worth as much as $US615 billion, but its shares have plunged on investor concerns about the company’s experimental drug pipeline and its ability to navigate challenges in the US market.“The stock has gone from being a market darling to one of its biggest…


Click here to view the original article.